- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | CITIUS ONCOLOGY, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.09. | CITIUS ONCOLOGY, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.08. | CTOR stock touches 52-week low at $1.67 amid market challenges | 1 | Investing.com | ||
| 16.08. | Citius Oncology Inc. completes strategic acquisition | 2 | Investing.com | ||
| 16.08. | CITIUS ONCOLOGY, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.08. | CTOR stock touches 52-week low at $3.20 amid market fluctuations | 1 | Investing.com | ||
| 13.08. | NSE - CITIUS ONCOLOGY, INC. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 1 | SEC Filings | ||
| 12.08. | Citius Pharmaceuticals, Inc.: Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. | 103 | PR Newswire | LYMPHIR for the treatment of cutaneous T-cell lymphoma approved by the FDA
Citius Pharmaceuticals, Inc. holds approximately 90% of publicly traded Citius Oncology, Inc.
Shares of Citius Oncology, Inc.... ► Artikel lesen | |
| 09.08. | CITIUS ONCOLOGY, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 09.08. | TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination with Citius Oncology, and Provides Market Update | 628 | GlobeNewswire (Europe) | New York, NY, Aug. 09, 2024 (GLOBE NEWSWIRE) -- On August 7, 2024, TenX Keane Acquisition (Nasdaq: TENKU, TENK, TENKR) ("TenX"), a publicly traded special purpose acquisition company, was notified by... ► Artikel lesen | |
| 05.08. | Citius Pharmaceuticals, Inc.: Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc. | 200 | PR Newswire | Citius Pharmaceuticals to receive 65.6 million shares of TenX Keane, which will be renamed Citius Oncology, Inc.
Citius Pharmaceuticals to retain approximately 90% majority control post transaction... ► Artikel lesen | |
| 24.10.23 | Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc. | 273 | GlobeNewswire (Europe) | Citius Pharmaceuticals, Inc. to receive $675 million in equity of Citius Oncology, Inc. and retain approximately 90% majority control in publicly listed Citius Oncology, Inc. post transaction Transaction... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 29,500 | 0,00 % | PESG Research: PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch | With its focus on targeting well-defined subgroups by inhibiting SRC/YES1 kinases in Non Small-Cell Lung Cancer patients resistant to EGFR and ALK targeted therapies, Nuvectis Pharma's NXP900 could... ► Artikel lesen | |
| NUVALENT | 112,10 | 0,00 % | Nuvalent announces pricing of $500M upsized stock offering | ||
| BIONTECH | 112,90 | +1,71 % | Kurssprung bei Medigene! "Short-Squeeze" bei Evotec? BioNTech Aktie verkaufen? | Über 10 % konnte die Aktie von Medigene gestern zwischenzeitlich zulegen. Auslöser für den Kurssprung war, dass das Biotech-Unternehmen in den USA einen Meilenstein erreicht hat. Die FDA hat das Hauptprogramm... ► Artikel lesen | |
| IMMUNEERING | 2,845 | 0,00 % | Pre-market Movers: Tenon Medical, Vision Marine Technologies, SMX, Singular Genomics Systems, Immuneering | SAN JOSE (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.00 A.M. ET).In the Green Tenon Medical, Inc. (TNON) is up over 350% at $19.80.
Vision... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,180 | 0,00 % | Adma biologics director sells shares worth over $166k | ||
| CG ONCOLOGY | 36,990 | +6,31 % | CG Oncology surges 7%; seen benefitting from J&J bladder cancer asset data | ||
| ITEOS THERAPEUTICS | 12,100 | 0,00 % | iTeos Therapeutics Inc.: iTeos gibt klinisch bedeutsame objektive Ansprechrate bekannt - Beobachtung bei jeder Dosis in der Zwischenanalyse des Nachbeobachtungszeitraums der GALAXIES Lung-201-Studie zu Belrestotug + Dostarlimab bei Patienten mit nicht-kle | - Klinisch bedeutsame objektive Ansprechrate (Objective Response Rate, ORR) von 63,3-76,7 % bei der Kombination von Belrestotug + Dostarlimab, mit einer bestätigten ORR (confirmed ORR, cORR) von ca.... ► Artikel lesen | |
| INSTIL BIO | 63,99 | 0,00 % | Instil Bio: Waschechter Tenbagger für den NBC! | Die Erfolgsgeschichte des exklusiven No Brainer Clubs (NBC) setzt sich fort: Mit Instil Bio hat der NBC erneut einen absoluten Volltreffer gelandet, der Mitgliedern je nach Einstiegszeitpunkt +736 bis... ► Artikel lesen | |
| TANGO THERAPEUTICS | 9,610 | 0,00 % | Analyst Scoreboard: 4 Ratings For Tango Therapeutics | ||
| ZENTALIS PHARMACEUTICALS | 3,670 | 0,00 % | Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies | SAN DIEGO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 35,550 | -5,05 % | SpringWorks Therapeutics, Inc.: FDA Grants Priority Review to SpringWorks Therapeutics' New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN | - PDUFA target action date of February 28, 2025 - - EU Marketing Authorization Application also validated by European Medicines Agency - STAMFORD, Conn., Aug. 28, 2024 (GLOBE NEWSWIRE) -- SpringWorks... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 24,590 | +3,76 % | ArriVent BioPharma shares see boost as Citi ups price target | ||
| QIAGEN | 41,825 | +0,17 % | Biotech Report: Evotec leichter, Qiagen behauptet | (shareribs.com) Frankfurt / New York 10.09.2024 - Biotech-Aktien zeigen sich am Dienstag uneinheitlich. Im deutschen Handel legen Qiagen und 4SC zu, Evotec geben nach. Auch an der Wall Street gibt es... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 41,720 | 0,00 % | Unveiling 7 Analyst Insights On Avidity Biosciences | ||
| IMMUNOME | 15,780 | -1,44 % | Immunome, Inc.: Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024 | Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present a poster with updated... ► Artikel lesen |
Das Unternehmen CITIUS ONCOLOGY INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,150 (-8,47 %) liegt der Kurs bei 1,620 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CITIUS ONCOLOGY INC finden Sie auf Wallstreet Online.
